002793 Luoxin Pharmaceuticals Group Stock
- 4.79
- -0.13-2.64%
Luoxin Pharmaceuticals Group Stock News
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Biggest Owners Are Individual Investors Who Got Richer After Stock Soared 11% Last Week
Key Insights Luoxin Pharmaceuticals Group Stock's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 9 invest
Luoxin Pharmaceutical (002793.SZ): Net loss of 366.616 million yuan in the first quarter
Gelonghui, April 26 | Luoxin Pharmaceutical (002793.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 689 million yuan, up 3.97% year on year; net profit attributable to shareholders of listed companies - 366.616 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 389.5599 million yuan; basic earnings per share - 0.03 yuan.
Luo Xin Holdings, the controlling shareholder of Luoxin Pharmaceutical (002793.SZ), received an administrative penalty decision from the Zhejiang Securities Regulatory Bureau
According to the Zhitong Finance App, Luoxin Pharmaceutical (002793.SZ) announced that Shandong Luoxin Holdings Co., Ltd. (“Luoxin Holdings”), the controlling shareholder of the company, has received the “Administrative Penalty Decision” issued by the Zhejiang Regulatory Bureau of the China Securities Regulatory Commission. According to the decision, Luo Xin Holdings, as the shareholder of Luoxin Pharmaceutical Holdings, held 31.23% of Luoxin Pharmaceutical's shares as of May 17, 2023. From May 18 to 24, 2023, Luoxin Holdings reduced its holdings of Luoxin Pharmaceutical shares by a total of 62.25 million shares through a major transaction, accounting for 5.72% of Luoxin Pharmaceutical's total share capital. Luo Xin Holdings's total holdings reduction ratio reached
Luo Xin Holdings, the controlling shareholder of Luoxin Pharmaceutical (002793.SZ), received an advance notice of administrative penalties from the Zhejiang Securities Regulatory Bureau
Luo Xin Pharmaceutical (002793.SZ) announced that Luo Xin Holdings, the controlling shareholder of the company, recently received Zhejiang supervision from the China Securities Regulatory Commission...
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) 29% Share Price Surge Not Quite Adding Up
Luoxin Pharmaceuticals Group Stock Co., Ltd. (SZSE:002793) shareholders are no doubt pleased to see that the share price has bounced 29% in the last month, although it is still struggling to make up r
Luoxin Pharma Gets Right to Use Shenzhen Shishijijun Biotechnology's Fecal Microbiota Transplant Technology
Luoxin Pharmaceuticals Group (SHE:002793) agreed to receive the right to use Shenzhen Shishijijun Biotechnology's fecal microbiota transplant technology, according to a Thursday disclosure published o
Luoxin Pharmaceutical (002793.SZ) and Shenzhen Xbiome Biotech reached a strategic cooperation on commercialization of gut microbiota transplantation (FMT)
On March 7, 2024, the company signed a “Strategic Cooperation Framework Agreement” in Shenzhen with Shenzhen Xbiome Biotech Co., Ltd.
Here's Why Luoxin Pharmaceuticals Group Stock (SZSE:002793) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Luoxin Pharmaceutical (002793.SZ): The repurchase was completed with a cumulative cost of 999.8861 million yuan to repurchase 26.279 million shares
Gelonghui, Feb. 19 | Luoxin Pharmaceutical (002793.SZ) announced that as of February 8, 2024, the company had repurchased a total of 26.278.61 million shares of the company through a dedicated share repurchase account, accounting for 2.39% of the company's current total share capital. Among them, the highest transaction price of the repurchase was 421 yuan/share, the minimum transaction price was 3.52 yuan/share, and the total transaction amount was 999.8861 million yuan (excluding transaction fees). At this point, the implementation of the company's share repurchase plan has been completed. The actual time range for the company to repurchase shares is from February 5, 2024 to February 8, 2024
Luoxin Pharmaceutical (002793.SZ) has repurchased 2.39% of its shares at a total cost of 99.88 million yuan
Luoxin Pharmaceutical (002793.SZ) issued an announcement. As of February 7, 2024, the company has passed a share repurchase policy...
Luoxin Pharmaceutical (002793.SZ) has repurchased a total of 1.86% of its shares at a cost of about 78.43 million yuan
Luoxin Pharmaceutical (002793.SZ) issued an announcement. As of February 6, 2024, the company has passed a share repurchase policy...
Luoxin Pharmaceutical (002793.SZ): Plans to repurchase 50 million yuan to 100 million yuan of company shares
Gelonghui, Feb. 1 | Luoxin Pharmaceutical (002793.SZ) announced that it plans to repurchase the company's shares with a total capital of not less than RMB 50 million and no more than RMB 10,000 million. The repurchase price will not exceed RMB 7.62 per share.
Luoxin Pharmaceutical (002793.SZ): Expected net loss of 480 million yuan to 720 million yuan in 2023
On January 30, Gelonghui | Luoxin Pharmaceutical (002793.SZ) announced that it expects a net loss of 480 million yuan to 720 million yuan in 2023, after deducting non-net loss of 450 million yuan to 68 million yuan. During the reporting period, the company's profit was still at a loss, mainly because the company's innovative drug business was not able to cover its costs, and corresponding impairment preparations for inventory and long-term assets were calculated in accordance with accounting policies totaling 165.648 million yuan.
Luoxin Pharmaceuticals Posts Positive Results of Plucanatide Tablets' Trial
The phase III study of Luoxin Pharmaceuticals Group's (SHE:002793) unit, Shandong Luoxin Pharmaceutical Group, on plecanatide tablets showed positive results, the pharmaceutical company said in a Jan.
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Share Price Not Quite Adding Up
With a median price-to-sales (or "P/S") ratio of close to 3.2x in the Pharmaceuticals industry in China, you could be forgiven for feeling indifferent about Luoxin Pharmaceuticals Group Stock Co., Ltd
Luoxin Pharmaceutical won two awards: Leading Force • Pharmaceutical High Quality Development Achievement Enterprise and Brand
SHANGHAI, January 11, 2024/PRNewswire/ -- From January 10 to 12, the 35th Pharmaceutical Economic Information Conference hosted by the Southern Pharmaceutical Research Institute of the State Drug Administration and hosted by “Pharmaceutical Economic Daily” was held in Guangzhou. During the conference, the “Head Force • High Quality Pharmaceutical Development” series list was officially announced. Luoxin Pharmaceutical Group Co., Ltd. (“Luoxin Pharmaceutical” or “Company” for short) was awarded the “Leading Strength • Pharmaceutical High Quality Development Achievement Enterprise (2023)”, and Tigorasan tablets (trade name: Taixinzan), a national class 1 innovative drug in the field of digestion, were recognized as “Head Strength •
Luoxin Pharmaceutical (002793.SZ): As of December 20, 2023, the total number of shareholders of the company was 2,8256
Gelonghui December 25 | Luoxin Pharmaceutical (002793.SZ) said on an interactive platform that as of December 20, 2023, the total number of shareholders of the company was 28,256.
Combining Therapy to Eradicate Helicobacter Pylori! Luoxin Pharmaceutical's marketing application for new indications for Tigolacen tablets accepted
SHANGHAI, December 14, 2023/PRNewswire/ -- Recently, Luoxin Pharmaceutical Group Co., Ltd. (“Luoxin Pharmaceutical” for short), a key product in the field of digestive diseases, the national Class I innovative drug Tigorasan tablets (trade name: Taixinzan), a new indication for the “elimination of Helicobacter pylori in combination with appropriate antimicrobial therapy” was accepted by the State Drug Administration. This is the third marketing application submitted for Tigolaxen. The other two approved indications are reflux esophagitis and duodenal ulcer, respectively. Epidemiological studies of Helicobacter pylori infection show that more than half of the world
Luoxin Pharmaceutical (002793.SZ): Obtaining a Notice of Acceptance of the Marketing Application for New Indications for Tigoracen
Gelonghui, December 13|Luoxin Pharmaceutical (002793.SZ) announced that recently, Shandong Luoxin Pharmaceutical Group Co., Ltd., a subsidiary of Luoxin Pharmaceutical Group Co., Ltd., received a “Notice of Acceptance” for the marketing application of tigolacin tablets “combined with appropriate antimicrobial therapy to eradicate Helicobacter pylori” from the State Drug Administration. Tigolasen tablets are potassium-ion competitive acid blockers (P-CAB), and their mechanism of action to inhibit acid secretion is to competitively bind H in parietal cells
Luoxin Pharmaceutical, where expansion and contraction coexist, is struggling to commercialize innovative drugs
“Investor Network” Cai Jun once had ambitious Luoxin Pharmaceutical (002793.SZ, hereinafter referred to as the “Company”), is now confused. Luoxin Pharmaceutical is a design and manufacturing enterprise integrating production and scientific research. In December of this year, the company announced that the controlling party, Luoxin Holdings, had received a filing notice from the Securities Regulatory Commission for allegedly transferring securities in violation of restrictive regulations. Specifically, when the shareholding ratio of Luo Xin Holdings changed by 5%, it failed to promptly fulfill its information disclosure obligations in accordance with regulations and stopped related transactions. As of the third quarter of this year, Luo Xin Holdings held 21.79% of the company's shares. The company stated that the case was filed against the holding party and its production
Analysis
Price Target
No Data
